Stoke is pioneering a new way to treat the underlying cause of severe genetic diseases by precisely upregulating protein expression. We develop antisense oligonucleotide medicines that increase gene expression to treat genetic epilepsies and other severe monogenic diseases, including genetic conditions affecting the central nervous system, eye, liver and kidney. We believe our proprietary technology platform, Targeted Augmentation of Nuclear Gene Output, or TANGO, will allow us to deliver disease-modifying therapies in a highly precise, durable and controlled manner. Source
No articles found.
Aeolus Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses o...
Aeolus Pharmaceuticals, Inc. is a biopharmaceut...
Tactile Medical is a leader in developing and marketing at-home therapy devices th...
Tactile Medical is a leader in developing and m...
Lipocine Inc. is a clinical-stage biopharmaceutical company focused on metabolic a...
Lipocine Inc. is a clinical-stage biopharmaceut...
Oramed Pharmaceuticals (NASDAQ: ORMP) was established in 2006, and has developed a...
Oramed Pharmaceuticals (NASDAQ: ORMP) was estab...
IMV Inc. is a clinical stage biopharmaceutical company dedicated to making immunot...
IMV Inc. is a clinical stage biopharmaceutical ...
BiondVax is an innovative biopharmaceutical company developing a universal flu vac...
BiondVax is an innovative biopharmaceutical com...
Synlogic⢠is pioneering the development of a novel class of living Synthetic Bio...
Synlogic⢠is pioneering the development of a ...
Join the National Investor Network and get the latest information with your interests in mind.